HANSHOW
27.3.2024 10:56:30 CET | Business Wire | Press release
From March 13th to 15th, the 24th China Retail Expo was held at Shanghai's National Convention and Exhibition Center. Under the theme "Green Digitalization and GenAI for Sustainable Retail," Hanshow debuted its pioneering GenAI product strategy, marking a significant leap forward in retail's AI era. The showcase included the upgraded Hanshow Polaris Pro series electronic shelf labels (ESL) and a new green digital store solution, reaffirming Hanshow's dedication to providing retailers with cutting-edge technologies for enhanced efficiency, improved shopper experiences, and sustainable practices.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240320389359/en/
The breakthrough of Generative Pre-trained Transformer 3 (GPT-3) technology, represented by represented by ChatGPT, has expanded the boundaries of all industries. Hanshow is Microsoft’s global strategy partner in the retail industry since 2023 and is one of the first to incorporate GenAI technology in retail scenarios using Azure OpenAI (AOAI).
At the event, Eason Tong, Dean of the Hanshow Retail Research Institute, announced Hanshow's first GenAI solution for retail business operations based on strategic cooperation with Microsoft. For retailers, Hanshow uses OpenAI's large model capabilities integrated with massive digital retail data to create the industry's first automated content (copy + image) generation intelligent application solution - the Hanshow Store Marketing Assistant.
The GenAI solution released by Hanshow relies on open source GPT-4 text output and Dall-E3 image output and can generate commodity POP posters, marketing atmosphere posters, and product copy through dialogue interaction. The internal integration of Hanshow's product ecosystem allows the generated materials to be uploaded and shown on the Hanshow Lumina Screen and upcoming large-sized colorful electronic paper posters with one click.
With the Hanshow Store Marketing Assistant, stores can easily generate a variety of creatively designed marketing materials to vividly portray product selling points while controlling marketing costs and improving sales. Whether it is a store operator or a brand owner, retailers can use the solution to reduce creative work from several hours to a few minutes.
"Hanshow is dedicated to offering retailers a retail media network solution that diversifies income streams. Leveraging generative AI for content, personalization, and impact assessment, we support future store media networks comprehensively," said Tong.
Microsoft and its ecosystem have supported Hanshow in building a digital store solution based on Azure OpenAI capabilities, and the two parties are deepening their cooperation and accelerating the landing of generative AI in global physical retail scenarios.
Microsoft and Hanshow jointly held a high-level roundtable forum to explore revolutionary omnichannel GenAI retail applications and trends and the green development and digital transformation of the retail industry.
"GenAI's remarkable capabilities are revolutionizing various industries. We're delighted to see Hanshow, Microsoft's global strategic partner, leveraging Azure OpenAI technology to introduce generative AI into physical retail. As a pioneer in retail digitalization, Hanshow combines industry insights with GenAI to present innovative digital store solutions," stated Frank Kong, Microsoft China's General Manager of Retail Consumer Goods.
Coming up, Hanshow and Microsoft’s GenAI marketing solutions for consumers will also be unveiled at the NRF exhibition in Singapore in June 2024, covering the four areas of store operations, consumer experience, store media, and green energy.
About Hanshow
Hanshow is one of the global leaders in the development and manufacturing of electronic shelf labels and digital store solutions. The company offers customers a series of customized IoT touchpoints and digital store solutions that deliver customer-centric insights. Hanshow's solutions have provided services to a vast number of stores across more than 50 countries and regions, helping them streamline operations, optimize pricing strategies, and offer consumers a more personalized experience. Learn more: www.hanshow.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240320389359/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom